Europe Backs Meningitis B Booster for Teens
The EU medicines regulator recommends a single Bexsero booster dose for children aged 10 and over.
Updated on Nov. 13, 2026 in COVID-19
Live Poll
Would you get your teenager a meningitis B booster if your doctor recommended it?
Europe's medicines regulator has recommended GSK's Bexsero meningitis B vaccine as a single booster dose for children aged 10 and over who received Bexsero at least two years earlier. The European Commission will make the final approval decision on the booster label.
Why it matters
In Europe, serogroup B is the leading cause of meningococcal disease in every age group under 65, and teenagers and young adults form a second peak of infection because they socialise closely. The recommendation rests on data showing infant immunity can be topped up with a single dose as much as 19 years later.
The late-stage trial enrolled 312 people aged 10 to 20, including 234 vaccinated as babies and 78 never previously vaccinated, and met its main goal of a stronger immune response in infant-vaccinated people than in unvaccinated first-dose recipients. The European Commission's final decision on the booster label remains pending.
The players
GSK
GSK is a British multinational pharmaceutical company that developed and markets the Bexsero meningitis B vaccine.
European Medicines Agency
The European Medicines Agency is the EU body responsible for the scientific evaluation and supervision of medicines, and its Committee for Medicinal Products for Human Use (CHMP) issued the recommendation.
European Commission
The European Commission is the executive arm of the European Union, which usually follows the EMA's advice when granting final approval for medicines.
The details
The CHMP backed adding the booster to the Bexsero label for people who received the vaccine at least two years earlier. Side effects in the trial were in line with the vaccine's known safety profile, and Bexsero is registered in 61 countries with about 140 million doses distributed since 2015.
Timeline
2015: Bexsero doses began being distributed across markets.
November 13, 2026: The CHMP recommendation of the teenage booster was reported.
Health Landscape
Bexsero is already part of 15 European infant immunisation programmes and three national teenage programmes, so the booster would extend an established vaccination framework rather than introduce a new one. Serogroup B remains the leading cause of meningococcal disease in Europe for every age group under 65, which is the health problem these programmes target.
Teenagers and children aged 10 and over who received Bexsero at least two years ago may become eligible for a single booster dose if the European Commission approves the label change. The booster is intended to maintain protection from infant vaccination against serogroup B meningitis, which is most dangerous for those in close-contact settings like schools and universities.
The takeaway
Parents of children who received the Bexsero infant series should check whether their teenagers have had a booster, since the vaccine's protection can be topped up with a single dose. The recommendation shows that early vaccination can be extended into adolescence with a simple additional dose.
What happens next
The European Commission is expected to make the final approval decision on the Bexsero booster label.
Further reading
For more on related immunisation developments, see the COVID-19 section.
Source note: This article includes information reported by The Market Reporter.
Live Poll
Would you get your teenager a meningitis B booster if your doctor recommended it?
